Cofactor Genomics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Missouri, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4044 Clayton Ave, St. Louis, Missouri, 6...Phone Number
(314) 531-4647Website
www.cofactorgenomics.comRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Cofactor Genomics
Cofactor Genomics specializes in RNA-Seq technology, focusing on predictive diagnostics that match cancer patients to appropriate treatments. They have developed the OncoPrism assay, which accurately predicts patient responses to immunotherapy, and are currently involved in clinical trials with over 24 healthcare systems. Their innovative approach utilizes multidimensional biomarkers to enhance the understanding of tumor responses, aiming to improve precision medicine. The company targets medical oncologists, pathologists, and clinical researchers interested in immune-oncology indications.Explore more
Cofactor Genomics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cofactor Genomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cofactor Genomics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Cofactor Genomics has new funding data
Cofactor Genomics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Cofactor Genomics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cofactor Genomics
Earning: See what the market has to say on Cofactor Genomics recently announced quarterly report
Check if Cofactor Genomics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Cofactor Genomics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Cofactor Genomics
Compare insights from companies similar to Cofactor Genomics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cofactor Genomics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cofactor Genomics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cofactor Genomics.
Cofactor Genomics financials insights
Gather financial insights about Cofactor Genomics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Other Financing Round
$2.6M
Other Financing Round
$120K
2017
Series A
$18M
2020
Debt
$350K
2021
Debt
$424K
Cofactor Genomics Tech Stack
A closer look at the technologies used by Cofactor Genomics
See more technologies
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Open Position
Funding
Cofactor Genomics has received an SBA PPP loan in the amount of $424,807 from Silicon Valley Bank resulting in the retention of 14 jobs.
Funding
Cofactor Genomics News & Media
Cofactor Genomics Publishes Analytical Validation of OncoPrism-HNSCC, Highlighting Robustness of The AI-powered RNA Test In Predicting Cancer Patient Response To Immunotherapy
SAINT LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their analytical validation study of the OncoPrism®-HNSCC test on the heels of its successful clinical validation and Medicare Reimbursement. OncoPrism-HNSCC predicts benefit from immune checkpoint inhibitors (ICIs) for patients with recurrent/metastatic squamous cell carcinoma of the head and neck, a critically needed tool for a patieCofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test
ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been named CEO and Board Member to lead Cofactor’s plan to bring precision medicine to immunotherapy. Simultaneously, the company announced that Jarret Glasscock, scientist and Cofactor Genomics founder, will transition into the role of President, Chief Technology Officer (CTO), and Board Member. Parker jCofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer Patients
ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism®-NSCLC, an RNA-based diagnostic to predict response to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients. The validation of OncoPrism-NSCLC follows the recent announcement of Medicare coverage for Cofactor’s OncoPrism-HNSCC test. Both tests use Cofactor’s Health Expression ModelsCofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to Immunotherapy
ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their PREDAPT clinical trial (NCT04510129) results in head and neck squamous cell carcinoma (HNSCC). The publication describes the clinical validity and utility of OncoPrism-HNSCC, a Medicare-reimbursed test that predicts benefit from immune checkpoint inhibitors (ICI). The multicenter study reports a 300% improvement in specificity over
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cofactor Genomics
Sign Up For FreeTo access detailed company insights
Cofactor Genomics specializes in RNA-Seq technology, focusing on predictive diagnostics that match cancer patients to appropriate treatments. They have developed the OncoPrism assay, which accurately predicts patient responses to immunotherapy, and are currently involved in clinical trials with over 24 healthcare systems. Their innovative approach... Read More
